QuidelOrtho Adds Fentanyl Test to Its Vitros® Systems as a MicroTip® Partnership Assay
2024年4月10日 - 8:00PM
ビジネスワイヤ(英語)
Helping hospital and emergency room
customers respond to the critical demand for enhanced opioid
testing
QuidelOrtho Corporation (Nasdaq: QDEL) has added the ARK™
Fentanyl II Assay to its U.S. Vitros® XT 7600 and 5600 Integrated
Systems as well as its Vitros® 4600 Chemistry System menu of assays
as a MicroTip® Partnership Assay (“MPA”). This Fentanyl assay will
help hospital and emergency room customers respond to the critical
demand for enhanced opioid testing, allowing on-site fentanyl
testing in less than 10 minutes to aid in immediate clinical
decisions.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240410125315/en/
QuidelOrtho Vitros® XT 7600 Integrated
System (Photo: Business Wire)
According to the Centers for Disease Control and Prevention
(“CDC”), the number of fatalities resulting from fentanyl overdoses
has tripled from 2016 to 2021, with an ongoing upward trend.1 The
CDC highlights California, Florida, New York, Pennsylvania and Ohio
as states with the highest mortality rates attributed to fentanyl.1
Consequently, several states have responded by implementing
regulations requiring fentanyl testing to be included as a required
component of drugs-of-abuse test panels.
“This assay transforms laboratory efficiency by integrating
fentanyl testing with existing protocols to eliminate the need for
external screening tests, and consolidates a lab’s drugs-of-abuse
panel into a singular, streamlined system, reducing intervention
time and ultimately helping to save lives,” said Lily Li, senior
director of medical and clinical affairs at QuidelOrtho. “Our
relentless commitment to diagnostics lies in empowering our
customers with impactful assays, particularly those capable of
delivering rapid drugs-of-abuse detection amidst the escalating
opioid crisis.”
Ninety percent of fentanyl is excreted as norfentanyl, which is
a synthetic opioid and is not detected on standard drug screening.1
The ARK™ Fentanyl II Assay provides preliminary analytical test
results by detecting this major metabolite, reducing the risk of
false negatives. As part of QuidelOrtho’s Vitros systems’ menu of
assays, the test offers clinical fentanyl testing for hospitals and
emergency departments, providing an effective approach to
preliminary urine drug testing.
Drug test results obtained in emergency departments play a
crucial role in addressing unique hospital challenges. When
patients test positive for opioids on a standard drug test, they’re
usually directed to drug treatment programs. However, these
standard tests fail to identify synthetic opioids, such as
fentanyl.1 Without specifically testing for fentanyl, instances of
fentanyl exposure might be disregarded, potentially leading to
missed opportunities for life-saving interventions like
administering naloxone, an opioid overdose reversal medication.
“Substance use is always changing, and medicine must change to
address the problems our patients face,” said Dr. Zachary Dezman, a
collaborating ED physician in Baltimore and Assistant Professor
with the University of Maryland School of Medicine, after working
with the Cesar Center for Substance Abuse, Addiction and Health
Research.2 “We cannot treat a problem if we don’t detect it."
- Center for Disease Control and Prevention. Opioid overdose.
Accessed March 28, 2024.
https://www.cdc.gov/drugoverdose/deaths/opioid-overdose.html
- CESAR Center for Substance Abuse, Addiction and Health
Research. UMD-led system shows success in helping hospitals
understand fentanyl use in their communities. Accessed March 29,
2024.
https://cesar.umd.edu/feature/umd-led-system-shows-success-helping-hospitals-understand-fentanyl-use-their-communities
Resources:
- Global MPA Website – MicroTip Partnership Assays (MPAs) |
QuidelOrtho
About QuidelOrtho Corporation
QuidelOrtho Corporation (Nasdaq: QDEL) is a world leader in in
vitro diagnostics, developing and manufacturing intelligent
solutions that transform data into understanding and action for
more people in more places every day.
Offering industry-leading expertise in immunoassay and molecular
testing, clinical chemistry and transfusion medicine, bringing
fast, accurate and reliable diagnostics when and where they are
needed – from home to hospital, lab to clinic. So that patients,
clinicians and health officials can spot trends sooner, respond
quicker and chart the course ahead with accuracy and
confidence.
Building upon its many years of groundbreaking innovation,
QuidelOrtho continues to partner with customers across the
healthcare continuum and around the globe to forge a new diagnostic
frontier. One where insights and solutions know no bounds,
expertise seamlessly connects and a more informed path is
illuminated for each of us.
QuidelOrtho is advancing diagnostics to power a healthier
future.
For more information, please visit www.quidelortho.com.
Source: QuidelOrtho Corporation
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240410125315/en/
Investor Contact: Juliet Cunningham Vice President, Investor
Relations IR@QuidelOrtho.com
Media Contact: D. Nikki Wheeler Senior Director, Corporate
Communications media@QuidelOrtho.com
QuidelOrtho (NASDAQ:QDEL)
過去 株価チャート
から 4 2024 まで 5 2024
QuidelOrtho (NASDAQ:QDEL)
過去 株価チャート
から 5 2023 まで 5 2024